Paper Details

  1. Home
  2. Paper Details

Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease.

Author: KaczynskiRichard, LyketsosConstantine G, MohamedSomaia, RosenheckRobert, SchneiderLon S, SultzerDavid L

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study used data from the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) trial to evaluate the effect of atypical antipsychotics versus placebo on caregiver burden. Caregivers of patients treated with atypical antipsychotics reported lower levels of burden, and this was mediated by improvement in patient agitation, hostility, and psychotic distortions.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Alzheimer's disease (AD) imposes a severe burden upon patients and their caregivers. Severity of psychiatric symptoms and behavioral disturbances is an important determinant of caregivers' experience of burden. These symptoms may be improved with atypical antipsychotic treatment. OBJECT...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/21939611

データ提供：米国国立医学図書館（NLM）

The Impact of Antipsychotics on Caregiver Burden in Alzheimer's Disease

Alzheimer's disease (AD) is a devastating neurodegenerative disorder that profoundly impacts both patients and their caregivers. This study investigates the effects of second-generation antipsychotics on caregiver burden in patients with AD. The researchers analyzed data from a clinical trial involving [number] patients with AD and their caregivers, finding that second-generation antipsychotics were associated with a significant reduction in caregiver burden. This research is like a beacon of hope, illuminating the challenges faced by caregivers of individuals with AD and offering potential solutions to alleviate the burden.

Easing the Burden: Antipsychotics and Caregiver Support

This study highlights the potential benefits of second-generation antipsychotics in reducing caregiver burden in patients with AD. The researchers found that these medications significantly improved caregiver experiences, suggesting a promising approach for supporting both patients and their caregivers. This research is like a refreshing spring in the desert of Alzheimer's care, offering a potential oasis of relief for caregivers.

A Collaborative Approach to Alzheimer's Care

This study underscores the importance of a collaborative approach to Alzheimer's care, involving healthcare professionals, caregivers, and patients. By working together, we can develop more effective treatment strategies and provide better support for individuals with AD and their families. It's like building a resilient caravan in the desert of Alzheimer's, ensuring that everyone involved has the necessary resources and support to navigate this challenging journey.

Dr. Camel's Conclusion

This study provides valuable insights into the challenges faced by caregivers of individuals with AD and highlights the potential of second-generation antipsychotics to alleviate the burden. It's like discovering a hidden oasis of support in the vast desert of Alzheimer's care, offering hope and a path towards a more fulfilling experience for both patients and their loved ones.

Date :
  1. Date Completed 2012-04-03
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

21939611

DOI: Digital Object Identifier

NIHMS445643

Related Literature

Article Analysis
・Effective treatment of alzheimer's disease
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.